HeartFocus (V.1.1.1)
K242807Deski · cleared 2025-04-04 · product code QJU · Radiology
Premarket evidence — what FDA accepted
source quote (p.5)
“The HeartFocus software is a radiological computer-assisted acquisition guidance system that provides real-time user guidance during echocardiography to assist the user in acquiring anatomically standard diagnostic-quality 2D echocardiographic views. HeartFocus software is an accessory to compatible general-purpose diagnostic ultrasound systems. HeartFocus is an application that operates entirely offline, without requiring a cloud server to provide its functionalities. All collected medical data is stored locally on the tablet. This data is never transferred to a server controlled by DESKi. HeartFocus uses artificial intelligence (AI) to emulate the expertise of sonographers in positioning the probe on the patient's chest and in identifying and recording diagnostic-quality clips.”
source quote (p.6)
“HeartFocus uses artificial intelligence (AI) to emulate the expertise of sonographers in positioning the probe on the patient's chest and in identifying and recording diagnostic-quality clips. The guidance UI is generated by a machine learning model that infers the probe's position relative to the target position, i.e. that would provide diagnostic-quality images. Both systems apply deep learning based algorithms to emulate the expertise of a sonographer by providing real-time guidance on how to position the transducer on the patient's body.”
source quote (p.21)
“The modification is limited to retraining with additional data without changing the models' architecture or training procedure.”
source quote (p.1)
“FDA's substantial equivalence determination also included the review and clearance of your Predetermined Change Control Plan (PCCP).”
Validation studies (3)
Bench
n=31 other
endpoints: demonstrate that the HeartFocus user interface is safe and effective for the intended users, uses, and use environments
standards: FDA Guidance Document, « Applying Human Factors and Usability Engineering to Medical Devices », IEC 62366 1:205 standard
Standalone
n=290 patients
endpoints: accurately detect anatomical structures of the heart in ultrasound images to indicate whether they can be used to guide the user; maximize the likelihood of capturing high-quality records; provide a relevant estimate of recording quality; automatically record clips identified to be of diagnostic quality by experts
Prospective clinical
n=240 patients · 2 site(s)
endpoints: Qualitative visual assessment of left ventricular (LV) size; Qualitative visual assessment of LV function; Qualitative visual assessment of right ventricular (RV) size; Qualitative visual assessment of the presence of non-trivial pericardial effusion
standards: ACEP scale (ACEP ≥ 3, Liu, R. B. et al. Emergency Ultrasound Standard Reporting Guidelines)
Reported performance (5 observations)
source quote (p.20)
“99.7% of the clips recorded with the “Auto record” feature were of diagnostic quality, demonstrating the high specificity of this feature.”
source quote (p.15)
“Cohen's kappa scores range from 0.699 [0.673, 0.724] to 0.873 [0.861, 0.884], meeting the success criteria of Cohen's kappa score > 0.6 on the lower bound of the 95% CI for each reference view.”
source quote (p.15)
“Guidance cues PPV ranges from 0.810 [0.804, 0.816] to 0.953 [0.951, 0.955], satisfying the success criteria of PPV > 0.8 on the lower bound of the 95% CI for each reference view.”
source quote (p.15)
“While using the Auto record feature solely, the PPV ranges from 0.846 [0.665, 0.938] to 1.000 [0.908, 1.000], meeting the success criteria of PPV > 0.6 on the lower bound of the 95% CI and PPV > 0.8 on the point estimate for each reference view.”
source quote (p.15)
“While using both the Auto record and Best-Effort record, the PPV ranges from 0.816 [0.666, 0.908] to 1.000 [0.914, 1.000].”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device); a recall is shown as device-attributed only when the recall record itself lists this clearance number. Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).
Applicable FDA guidance — what the submission is measured against
FDA guidance documents and guiding principles applicable to 510(k) AI/ML devices in the Radiology panel. A curated reference index, not legal or regulatory advice — each item states its own status, and a draft is never binding.
- Final guidanceRadiology-specific2022-09Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions
Radiology CADe/CADx · Software premarket content
Original July 2012; current database date reflects a Sept 2022 reissue. Governs CADe device 510(k) content.
- Final guidanceRadiology-specific2022-09Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions
Radiology CADe/CADx
Original July 2012, revised 2020; current database date Sept 2022. Covers standalone and reader-study performance assessment for CADe.
- Final guidanceRadiology-specific2022-06Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions
Quantitative imaging · Radiology CADe/CADx
Final (June 2022). Relevant to devices outputting quantitative imaging measurements.
- Final guidance2026-01Clinical Decision Support Software
Clinical decision support · SaMD (general)
New final guidance issued Jan 2026, superseding the Sept 2022 version; narrows the device-CDS scope. Applies to software that informs clinical management.
- Final guidance2026-01General Wellness: Policy for Low Risk Devices
SaMD (general) · Clinical decision support
Revised final (Jan 2026); now addresses noninvasive products estimating physiologic parameters (SpO2, BP, glucose). Reshapes the device / non-device line for AI wellness features.
- Final guidance2025-09Computer Software Assurance for Production and Quality Management System Software
SaMD (general) · Postmarket
Final (Sept 2025). Covers software used in production/QMS (incl. ML development-pipeline tooling), superseding Section 6 of the 2002 GPSV — not device software functions themselves.
- Final guidance2025-06Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions
Cybersecurity · Software premarket content
Reissued June 2025 (retitled 'Quality Management System', was Sept 2023 'Quality System'); adds coverage of FD&C Act §524B cyber devices.
- Final guidance2024-12Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions
Predetermined Change Control Plan · AI/ML lifecycle · Software premarket content
Final (Dec 2024). Supersedes the April 2023 AI/ML PCCP draft.
- Final guidance2023-10Electronic Submission Template for Medical Device 510(k) Submissions
Software premarket content
eSTAR has been mandatory for 510(k)s since Oct 2023 — operationally unavoidable, though not AI-specific.
- Final guidance2023-08Off-The-Shelf Software Use in Medical Devices
Software premarket content · SaMD (general)
Final (Aug 2023). Applies when a device incorporates off-the-shelf software components (common in ML stacks).
- Final guidance2023-06Content of Premarket Submissions for Device Software Functions
Software premarket content · SaMD (general)
Final (June 2023); replaced the May 2005 'Software Contained in Medical Devices' guidance. Documentation level drives the software content of the submission.
- Final guidance2022-09Policy for Device Software Functions and Mobile Medical Applications
SaMD (general) · Clinical decision support
Current version Sept 2022. Frames which software functions FDA regulates as devices.
- Final guidance2021-10De Novo Classification Process (Evaluation of Automatic Class III Designation)
De Novo pathway
Final (Oct 2021), issued with the De Novo final rule. Most relevant to first-of-a-kind devices without a predicate (DEN-numbered clearances).
- Final guidance2016-12Postmarket Management of Cybersecurity in Medical Devices
Cybersecurity · Postmarket
- Final guidance2002-01General Principles of Software Validation
SaMD (general) · Software premarket content
Still active except Section 6 (superseded Sept 2025 by the Computer Software Assurance final guidance).
- Draft guidance2025-01Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations
AI/ML lifecycle · Software premarket content · Transparency
Draft as of July 2026 (published Jan 2025); finalization is on CDRH's FY2026 agenda but not yet published. Treat as FDA's stated direction, not a binding expectation.
- Draft guidance2024-08Predetermined Change Control Plans for Medical Devices
Predetermined Change Control Plan · Postmarket
Draft (Aug 2024) extending PCCPs beyond AI to all devices under FD&C §515C; not final as of July 2026.
- Guiding principles2024-06Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
Transparency · AI/ML lifecycle
- Guiding principles2023-10Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles
Predetermined Change Control Plan · AI/ML lifecycle
FDA/Health Canada/MHRA joint principles (Oct 2023); companion to the GMLP and Transparency principles.
- Guiding principles2021-10Good Machine Learning Practice for Medical Device Development: Guiding Principles
AI/ML lifecycle · SaMD (general)
FDA/Health Canada/MHRA joint principles (Oct 2021). Foundational, not a binding guidance; IMDRF issued a related GMLP document Jan 2025.
Applicability is derived from the device's FDA advisory panel and pathway — cross-cutting guidances apply to every AI/ML device; panel-specific ones are flagged. Titles, dates, and links verified against fda.gov as of July 2026.